| __timestamp | Alnylam Pharmaceuticals, Inc. | Catalyst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 10117774 |
| Thursday, January 1, 2015 | 276495000 | 11801342 |
| Friday, January 1, 2016 | 382392000 | 11369941 |
| Sunday, January 1, 2017 | 390635000 | 11375237 |
| Monday, January 1, 2018 | 505420000 | 19919204 |
| Tuesday, January 1, 2019 | 655114000 | 18842752 |
| Wednesday, January 1, 2020 | 654819000 | 16496715 |
| Friday, January 1, 2021 | 792156000 | 16936000 |
| Saturday, January 1, 2022 | 883015000 | 19789000 |
| Sunday, January 1, 2023 | 1004415000 | 93150000 |
| Monday, January 1, 2024 | 1126232000 |
Igniting the spark of knowledge
In the competitive world of biopharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Alnylam Pharmaceuticals, Inc. has consistently outpaced Catalyst Pharmaceuticals, Inc. in R&D investment. From 2014 to 2023, Alnylam's R&D expenses surged by over 400%, peaking at approximately $1 billion in 2023. This reflects a strategic focus on pioneering RNA interference therapeutics. In contrast, Catalyst Pharmaceuticals, while showing a significant increase in 2023, with R&D expenses reaching nearly $93 million, has maintained a more conservative growth trajectory. This disparity highlights differing strategic priorities, with Alnylam aggressively pursuing new drug development, while Catalyst may be focusing on optimizing existing treatments. As the biopharmaceutical landscape evolves, these investment patterns could shape the future of medical breakthroughs and patient care.
Research and Development Expenses Breakdown: AstraZeneca PLC vs Catalyst Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. or Catalyst Pharmaceuticals, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Alnylam Pharmaceuticals, Inc. vs Summit Therapeutics Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Viatris Inc.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Geron Corporation
Analyzing R&D Budgets: BeiGene, Ltd. vs Catalyst Pharmaceuticals, Inc.
Analyzing R&D Budgets: Summit Therapeutics Inc. vs Catalyst Pharmaceuticals, Inc.
ADMA Biologics, Inc. vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Catalyst Pharmaceuticals, Inc. or Ligand Pharmaceuticals Incorporated: Who Invests More in Innovation?
Research and Development Investment: Catalyst Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.
Catalyst Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending